 |
| |
|
| |
| |
|
|
|
| Chemotherapy Protocols |
|
|
Due to the complex nature of the disease, cancer chemotherapy is a constantly evolving science. The fact remains that the scientific and medical community still has a long way to go before the battle against cancer can be won. Due to numerous factors, including the nature of the cancer cells, the staging and grading of the cancer etc, a cancer usually requires a combination of drugs for therapy. Even in the treatment of a cancer by multiple drugs, the cancer may develop resistance to therapy.
Numerous chemotherapy regimens have
evolved over time. The popularity of some of these has gained
in recent times supported by large scale randomized controlled
trials. As newer chemotherapy drugs are discovered, new regimens
would be introduced and studied till we have the perfect cure.
|
|
Listed below are some of the current popular chemotherapy regimens
featuring the drugs available in the Neiss Labs Product portfolio:-
|
|
Chemotherapy Protocols |
|
| |
| Protocol |
PBFuM |
| Cancer |
Head & Neck Cancer |
| Reference |
Amrein1 |
| PBFuM |
Cisplatin |
80 mg/m2, 24 h, day 1 |
| |
Bleomycin |
15 U, 24 h, day 1 |
| |
5-Fluorouracil |
800 mg/m2, 24 h, day 2-6 |
| |
Methotrexate |
100 mg/m2, day 16 |
| |
|
|
| |
3/4-week cycle, 2-4 cycles |
|
|
| |
| Protocol |
FuFaPB |
| Cancer |
Head & Neck Cancer |
| Reference |
Guaraldi2 |
| FuFaPB |
Cisplatin |
30 mg/m2, 1 h, day 1-2 |
| |
Folinic acid |
200 mg/m2, 1 h, day 1-2 |
| |
5-Fluorouracil |
500 mg/m2 bolus at half-infusion of Folinic acid, day 1-2 |
| |
Bleomycin |
15 U im, day 1-2 |
| |
|
|
| |
4-week cycle, ± 3 cycles |
|
|
| |
| Protocol |
ABVD |
| Cancer |
Hodgkin’s lymphoma |
| Reference |
Horning3 |
| |
|
|
| ABVD |
Doxorubicin |
25mg/m², day 1/15 |
| |
Bleomycin |
10 U/m², day 1/15 |
| |
Vinblastine |
6 mg/m², day 1/15 |
| |
Dacarbazine |
375 mg/m², days 1/15 |
| |
|
|
| |
4-week cycle, 6 cycles |
|
|
| |
| Protocol |
MOPP/ABV |
| Cancer |
Hodgkin’s lymphoma |
| Reference |
Glick4 |
| |
|
|
| MOPP/ABV |
Mechlorethamine |
6 mg/m², day 1 |
| |
Vincristine |
1.4 mg/m² (max. 2.4 mg), day 1 |
| |
Procarbazine |
100 mg/m² po, day 1-7 |
| |
Prednisone |
40 mg/m² po, day 1-14 |
| |
Doxorubicin |
25 mg/m², day 8 |
| |
Vinblastine |
6 mg/m², day 8 |
| |
Bleomycin |
10 U/m², day 8 |
| |
|
|
| |
4-week cycle, max. 12 cycles |
|
|
| |
| Protocol |
MACOP-B |
| Cancer |
Non-Hodgkin’s lymphoma |
| Reference |
Bayer5 |
| |
|
|
| MACOP-B |
Methotrexate |
400 mg/m², day 8 (with FA rescue 100 mg bolus, than 300 mg over 4h) |
| |
Doxorubicine |
50 mg/m², day 1 and 15 |
| |
Cyclophosphamide |
350 mg/m², day 1 and 15 |
| |
Vincristine |
1.4 mg/m² (max. 2.4 mg), day 8/22 |
| |
Prednisone |
75 mg po, daily for 12 weeks, than taper |
| |
Bleomycin |
10 U/m² day 22 |
| |
|
|
| |
4-week cycle, 3 cycles |
|
|
|
|
|
| |
| Protocol |
BEP |
| Cancer |
Testicular cancer |
| Reference |
Lehne6 |
| |
|
|
| BEP |
Bleomycin |
30 U bolus, once a week |
| |
Etoposide |
100 mg/m² over 30 min., day 1-5 |
| |
Cisplatin |
20 mg/m² over 30 min., day 1-5 |
| |
|
|
| |
3-week cycle, 3-4 cycles |
|
|
| |
| References: |
1. P. C. Amrein et al., Laryngoscope 102 (1992) 901.
2. M. Guaraldini et al. Ann. Oncol. 2 (1991) 379.
3. S. J. Horning et al., J. Clin. Oncol., 12 (1994) 297.
4. J. H. Glick et al., J. Clin. Oncol., 16 (1998) 19.
5. R. A. Bayer et al. Sem. Oncol., 19 (suppl. 5) (1992) 46.
6. G. Lehne et al., Br. J. Cancer 68 (1993) 555. |
| |
|
|
|
